Age-related decline in CD8<sup>+</sup> tissue resident memory T cells compromises antitumor immunity.

Pei, Siyu; Deng, Xiuyu; Yang, Ruirui; Wang, Hui; Shi, Jian-Hong; Wang, Xueqing; Huang, Jia; Tian, Yu et al. · Nat Aging · 2024

basic_science · Level V

Where this comes from

Abstract

Aging compromises antitumor immunity, but the underlying mechanisms remain elusive. Here, we report that aging impairs the generation of CD8<sup>+</sup> tissue resident memory T (T<sub>RM</sub>) cells in nonlymphoid tissues in mice, thus compromising the antitumor activity of aged CD8<sup>+</sup> T cells, which we also observed in human lung adenocarcinoma. We further identified that the apoptosis regulator BFAR was highly enriched in aged CD8<sup>+</sup> T cells, in which BFAR suppressed cytokine-induced JAK2 signaling by activating JAK2 deubiquitination, thereby limiting downstream STAT1-mediated T<sub>RM</sub> reprogramming. Targeting BFAR either through Bfar knockout or treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8<sup>+</sup> T cells by restoring T<sub>RM</sub> generation in the tumor microenvironment, thus efficiently inhibiting tumor growth in aged CD8<sup>+</sup> T cell transfer and anti-programmed cell death protein 1 (PD-1)-resistant mouse tumor models. Together, our findings establish BFAR-induced T<sub>RM</sub> restriction as a key mechanism causing aged CD8<sup>+</sup> T cell dysfunction and highlight the translational potential of iBFAR2 in restoring antitumor activity in aged individuals or patients resistant to anti-PD-1 therapy.

Medical subject headings